

## Certificate of Analysis

### DYRK1A, active

#### (Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-951, 14-951-K, 14-951M

Parent Lot # WAB0497

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal GST-tagged, recombinant, human DYRK1A, full length, expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose and gel filtration.

Purity 74% by SDS-PAGE and Coomassie blue staining. MW = 112kDa.

**Specific Activity (Parent lot# WAB0497):** 1924U/mg, where one unit of DYRK1A, active activity is defined as 1nmol phosphate incorporated into 50 $\mu$ M (RRRFRPASPLRGPPK) per minute at 30°C with a final ATP concentration of 100 $\mu$ M.

**Formulation:** 0.15mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 0.35–7.5ng of this lot of enzyme phosphorylated 50 $\mu$ M (RRRFRPASPLRGPPK) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed identity as DYRK1A with the translated sequence listed on page three



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **(RRRFRPASPLRGPPK):** Use at a final assay concentration of 50 $\mu$ M. Prepare a 2.5mM stock and add 0.5 $\mu$ l of stock per assay point.
3. **DYRK1A, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.35–7.5ng per assay point.
4. **[ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x MgAc/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

#### Assay Procedure (96 well plate format):

1. Add 5 $\mu$ l of 5 x reaction buffer per assay to wells.
2. Add 0.5 $\mu$ l of **(RRRFRPASPLRGPPK)**.
3. Add **2.5 $\mu$ l (0.35–7.5ng) DYRK1A, active**.
4. Add 7 $\mu$ l of dH<sub>2</sub>O.
5. Add 10 $\mu$ l of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 $\mu$ l of 3% phosphoric acid.
8. Transfer a 10 $\mu$ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

## Certificate of Analysis

### DYRK1A Sequence Information

|                         |                                                                     |
|-------------------------|---------------------------------------------------------------------|
| <b>Protein</b>          | human DYRK1A                                                        |
| <b>Tags</b>             | N-terminal GST                                                      |
| <b>Native sequence</b>  | M236 of the recombinant protein is equivalent to M1 of human DYRK1A |
| <b>Accession number</b> | GenBank NM_130436.2                                                 |

### Recombinant DYRK1A amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSM  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121  DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181  KRIEAIPOID  KYLKSSKYIA  WPLQGWQATF  GGDHPPKSD  LVPRGSKEFK  GLRRQMHTGG
241  ETSACKPSSV  RLAPSFSAHA  AGLQMAQOMP  HSHQYSDRRQ  PNISDQQVSA  LSYSDDIQQP
301  LTNQRRMPQT  FRDPATAPLR  KLSVDLIKTY  KHINEVYYAK  KRRRHQQGQG  DDSSHKKERK
361  VYNDGYDDDN  YDIYVKNGEK  WMDRYEIDSL  IGKGSFGQVV  KAYDRVEQEW  VAIKIIKNKK
421  AFLNQAQIEV  RLELMNKH  TEMKYYIVHL  KRHFMRNHL  CLVFEMLSYN  LYDLLRNTNF
481  RGVSLNLTRK  FAQQMCTALL  FLATPELSII  HCDLKPENIL  LCNPKRSAIK  IVDFGSSCQL
541  GQRIYQYIQS  RFYRSPEVLL  GMPYDLAIDM  WSLGCILVEM  HTGEPLFSGA  NEVDQMNKIV
601  EVLGIPPAHI  LDQAPKARKF  FEKLPDGTWN  LKKTGDGKRE  YKPPGTRKLH  NILGVETGGP
661  GGRRAGESGH  TVADYLKFKD  LILRMLDYDP  KTRIQPYIAL  QHSFFKKTAD  EGTNTSNSVS
721  TSPAMEQSQS  SGTTSSTSSS  SGGSSGTSNS  GRARSDPTHQ  HRHSGGHFTA  AVQAMDCETH
781  SPQVRQQFPA  PLGWSGTEAP  TQVTVETHPV  QETTFHVAPQ  QNALHHHHGN  SSHHHHHHHH
841  HHHHHGQQAL  GNRTRPRVYN  SPTNSSSTQD  SMEVGSHSHS  MTSLSSTTS  SSTSSSTGN
901  QGNQAYQNRP  VAANTLDFGQ  NGAMDVNLT  YSNPRQETGI  AGHPTYQFSA  NTGPAHYMTE
961  GHLTMRQGAD  REESPMTGVC  VQQSPVASS

```

### Recombinant DYRK1A nucleotide sequence:

```

1  atgtccccta  tactagggtta  ttggaaaatt  aagggccttg  tgcaaccac  tcgacttctt
61  ttggaatata  ttgaagaaaa  atatgaagag  catttgtatg  agcgcgatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatatgtat
181  ggtgatgtta  aattaacaca  gtctatggcc  atcatacggt  atatagctga  caagcacaac
241  atgttgggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcggttttg
301  gatattagat  acggtgtttt  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaaatgctg  aaaaatgctg  aagatcggtt  atgtcataaa
421  acatatattaa  atggtgatca  tgtaacccat  cctgacttca  tggttgatga  cgctcttgat
481  gttgttttat  acatggaccc  aatgtgcctg  gatgcgttcc  caaaattagt  ttgttttaaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacggtt  ggtgggtggc  accatctctc  aaaatcggat
661  ctggttccgc  gtggatccaa  ggaattcaaa  ggcctacgtc  gacaaatgca  tacaggagga
721  gagacttcag  catgcaaacc  ttcatctgtt  cggcttgcac  cgtcattttc  attccatgct
781  gctggccttc  agatggctgg  acagatgccc  cattcacatc  agtacagtga  ccgtcgtcag
841  ccaaacataa  gtgaccaaca  ggtttctgcc  ttatcatatt  ctgaccagat  tcagcaacct
901  ctaactaacc  agaggcggtg  gccccaaacc  ttccgtgacc  cagcaactgc  tcccctgaga
961  aaactttctg  ttgacttgat  caaaacatac  aagcatatta  atgagggtta  ctatgcaaaa
1021  aagaagcgaa  gacaccaaca  gggccaggga  gacgattcta  gtcataagaa  ggaacggaag
1081  gtttacaaat  atggttatga  tgatgataac  tatgattata  ttgtaaaaaa  cggagaaaag
1141  tggatggatc  gttacgaaat  tgactccttg  ataggcaaag  gttccttttg  acaggttgta
1201  aaggcatatg  atcgtgtgga  gcaagaatgg  gttgccatta  aaataataaa  gaacaagaag
1261  gcttttctga  atcaagcaca  gatagaagtg  cgacttcttg  agctcatgaa  caaacatgac
1321  actgaaatga  aatactacat  agtgcatttg  aaacgccact  ttatgtttcg  aaacctctc
1381  tgtttagtgt  ttgaaatgct  gtcctacaac  ctctatgact  tgctgagaaa  caccaatttc
1441  cgaggggtct  ctttgaacct  aacacgaaa  tttgcgcaac  agatgtgcac  tgcactgctt

```

## Certificate of Analysis

```

1501 ttccttgcca ctccagaact tagtatcatt cactgtgatc taaaacctga aaatatcctt
1561 ctttgtaacc ccaaacgcag tgcaatcaag atagttgact ttggcagttc ttgtcagttg
1621 gggcagagga tataccagta tattcagagt cgcttttatc ggtctccaga ggtgctactg
1681 ggaatgcctt atgaccttgc cattgatatg tggccctcg ggtgtatttt ggttgaaatg
1741 cacactggag aacctctgtt cagtgggtgcc aatgaggtag atcagatgaa taaaatagtg
1801 gaagttcttg gtattccacc tgctcatatt cttgaccaag caccaaaagc aagaaagttc
1861 tttgagaagt tgccagatgg cacttggaac ttaaagaaga ccaaagatgg aaaacgggag
1921 tacaaaccac caggaaccgc taaacttcat aacattcttg gagtggaac aggaggacct
1981 ggtgggagac gtgctgggga gtcagggtcat acggctcgctg actacttgaa gttcaaagac
2041 ctcatTTTTAA ggatgcttga ttatgacccc aaaactcgaa ttcaacctta ttatgctctg
2101 cagcacagtt tcttcaagaa aacagctgat gaaggtaaa atacaagtaa tagtgtatct
2161 acaagccccg ccatggagca gtctcagtct tcgggcacca cctccagtac atcgtcaagc
2221 tcagggtggct catcggggac aagcaacagt gggagagccc ggtcggatcc gacgcaccag
2281 catcggcaca gtggtgggca cttcacagct gccgtgcagg ccatggactg cgagacacac
2341 agtccccagg tgctgcagca atttcctgct cctcttggtt ggtcaggcac tgaagtcctt
2401 acacaggtca ctggtgaaac tcatcctggt caagaaacaa cctttcatgt agccctcaa
2461 cagaatgcat tgcatcatca ccatggtaac agttcccatc accatcacca ccaccaccac
2521 catcaccacc accatggaca acaagccttg ggtaaccgga ccaggccaag ggtctacaat
2581 tctccaacga atagctcctc taccgaagat tctatggagg ttggccacag tcaccactcc
2641 atgacatccc tgtcttcctc aacgacttct tcctcgacat cttcctcctc tactggtaac
2701 caaggcaatc aggcctacca gaatcgccca gtggctgcta ataccttga ctttgacag
2761 aatggagcta tggacgttaa tttgaccgtc tactccaatc cccgccaaga gactggcata
2821 gctggacatc caacatacca attttctgct aatacaggtc ctgcacatta catgactgaa
2881 ggacatctga caatgaggca aggggctgat agagaagagt ccccatgac aggagtttgt
2941 gtgcaacaga gtctctgtag tagctcgtaa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services